What's happening
This bill restores Medicaid pharmacy benefits to the state preferred drug program, aiming to control costs and improve drug access.
Why it matters
Centralizes Medicaid pharmacy benefits under the state’s preferred drug and clinical drug review programs. , which could boost New York’s negotiating power with drug manufacturers, potentially securing larger rebates and lower costs for taxpayers.
Limits the ability of prescribers to override the preferred drug list. , especially for drugs requiring mandatory generic substitution or those not supported by FDA-approved labeling or official reference compendia, aiming to prevent unnecessary use of costly or unproven medications.
Carves out an exception for prescriptions filled under the federal 340B program. , maintaining access to discounted drugs for certain safety-net providers while still applying state oversight through prior authorization and review processes.
Repeals provisions that previously allowed Medicaid managed care plans to handle pharmacy benefits independently. , signaling a move toward greater state control and uniformity in how Medicaid recipients access and are reimbursed for prescription drugs.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Expand Medicaid Drug Coverage
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to health
- Referred to health
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
3466
2023-2024 Regular Sessions
IN SENATE
January 31, 2023
Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the social services law, in relation to prescription drugs eligible for Medicaid coverage; to amend the public health law, in relation to prior authorization under the preferred drug program; to repeal certain provisions of part FFF of chapter 56 of the laws of
2020 directing the department of health to remove the pharmacy benefit from the managed care benefit package, relating to restoring such benefits; and to repeal certain provisions of the social services law, relating to coverage for certain prescription drugs under Medicaid managed care programs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Legislative findings. This legislature finds that the costs of many prescription drugs in the market have been escalating unreasonably. The preferred drug program and the clinical drug review program under the public health law provide effective mechanisms for assuring access to quality, effective and safe drugs to patients at reasonable cost. Providing prescription drugs to Medicaid managed health care provider participants through these programs will maximize the Medicaid program's ability to negotiate more substantial rebates with drug manufacturers (effectively, lower prices), while protecting Medicaid managed care provider participants.
§ 2. Sections 1 and 1-a of part FFF of chapter 56 of the laws of 2020, relating to prescription drugs under the Medicaid program, are REPEALED.
§ 3. The social services law is amended by adding a new section 365-i to read as follows:
§ 365-i. Prescription drugs in Medicaid. 1. The definitions of terms in section two hundred seventy of the public health law shall apply to this section. As used in this section, unless the context clearly requires otherwise, "managed care provider" means a managed care provider under section three hundred sixty-four-j of this article, or a managed long term care plan under section forty-four hundred three-f of the public health law.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD06159-01-3
2. Prescription drugs eligible for reimbursement under this article shall be provided and paid for under the preferred drug program and the clinical drug review program under title one of article two-A of the public health law, except as otherwise provided in subdivision three of this section.
3. This subdivision applies where the eligible individual is enrolled in a managed care provider and a prescription for the eligible individual is made under section 340B of the federal Public Health Service Act (the "340B program"). The managed care provider shall pay for the drugs under the 340B program. However, the prescription shall be subject to section two hundred seventy-three (preferred drug program prior authorization) and section two hundred seventy-four (clinical drug review program) of the public health law.
4. The managed care provider shall account to and reimburse the department for the net cost to the department for prescription drugs provided to eligible individuals who receive medical services from the managed care provider. Capitation payments by the department to such managed care provider shall include a component for reimbursements paid under this subdivision.
§ 4. Paragraph (b) of subdivision 3 of section 273 of the public health law, as added by section 10 of part C of chapter 58 of the laws of 2005, is amended to read as follows:
(b) In the event that the patient does not meet the criteria in paragraph (a) of this subdivision, the prescriber may provide additional information to the program to justify the use of a prescription drug that is not on the preferred drug list. The program shall provide a reasonable opportunity for a prescriber to reasonably present his or her justification of prior authorization. If, after consultation with the program, the prescriber, in his or her reasonable professional judgment, determines that the use of a prescription drug that is not on the preferred drug list is warranted, the prescriber's determination shall be final. However, the prescriber's determination shall not be final: (i) where the preferred drug is a generic drug subject to subparagraph (i) of paragraph (a-1) of subdivision four of section three hundred sixty-five-a of the social services law (mandatory generic substitution), and even if the prescriber has indicated that the prescription shall be dispensed as written; or (ii) if it is for the use of a drug that is not consistent with food and drug administration-approved labeling or supported by one or more official Compendia references, including, but not limited to, the American Hospital Formulary Service (AHFS), the DRUGDEX Drug Information System and the United States Pharmacopeia.
§ 5. Subdivisions 25, 25-a, 26 and 26-b, and paragraph (u) of subdivision 4 of section 364-j of the social services law are REPEALED.
§ 6. Severability. If any provision of this act, or any application of any provision of this act, is held to be invalid, or to violate or be inconsistent with any federal law or regulation, that shall not affect the validity or effectiveness of any other provision of this act, or of any other application of any provision of this act, which can be given effect without that provision or application; and to that end, the provisions and applications of this act are severable.
§ 7. This act shall take effect immediately, except that sections one through five of this act shall take effect on the one hundred eightieth day after they shall have become a law. Effective immediately, the commissioner of health shall make regulations and take other actions reasonably necessary to implement this act when it takes effect.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the social services law, in relation to prescription drugs eligible for Medicaid coverage; to amend the public health law, in relation to prior authorization under the preferred drug program; to repeal certain provisions of part FFF of chapter 56 of the laws of 2020 directing the department of health to remove the pharmacy benefit from the managed care benefit package, relating to restoring such benefits; and to repeal certain provisions of the social services law, relating to coverage for certain prescription drugs under Medicaid managed care programs
Purpose
Provides for coverage for prescription drugs under Medicaid
Summary of specific provisions
Section 1 provides the legislative findings regarding the escalating costs of many prescription drugs.
Read the full memo (854 words)
Section 2 repeals sections 1 and 1-a of part FFF of chapter 56 of the laws of 2020 as it relates to prescription drugs under the Medicaid program.
Section 3 adds a new section 365-i to the social services law as it relates to prescription drugs under Medicaid. This section provides language for reimbursement eligibility for prescription drugs and for drugs under the 340B program.
Section 4 amends paragraph (b) of subdivision 3 of section 273 of the public health law as it relates to prescription drugs not on the preferred drug list. When a patient's health care provider prescribes a prescription drug that is not on the preferred drug list, the prescriber may submit additional information to the program to justify their deci- sions. Ultimately, the provider's decision to warrant the use of a prescription not on the preferred list shall be final unless the prescription is for a generic medication or the drug is not consistent with the Food and Drug Administration labeling requirements or supported by official Compendia references.
Section 5 repeals subdivisions 25, 25-a, 26, and 26-b, and paragraph (u) of subdivision 4 of section 364-j of the social services law as it relates to prescription drugs prescribed by managed care providers.
Section 6 provides the severability clause. Section 7 provides the effective date.
Justification
The Preferred Drug Program (PDP) was established in 2005. Under the PDP, the clinical Drug Review Board (DRB) evaluates the clinical effective- ness and safety of drugs, the potential impact on patient care, and the health of special populations considering the latest peer-reviewed research. The DRB may place a drug or class of drugs either on the preferred drug list (PDL) or require prior authorization, which if declined, may be overcome using "prescriber prevails," so that a pres- criber can make sure that the patient receives the needed medication. The PDP initially administered the drug benefit for the whole Medicaid program, including Medicaid managed care.
During the several years that the PDP operated for all Medicaid patients, very few prescriptions were for non-preferred drugs because; (a) prescribers had confidence in the legitimacy of the list, (b) the required consultation with the system was enough of a "speed bump" that prescribers stuck to the list unless they felt strongly otherwise, and (c) drug companies were willing to pay the required rebates to get their drugs on the list, at an estimated average of $2B per year.
In 2011, the Legislature enacted the Cuomo administration's proposal to end the carve-out and instead have each Medicaid managed care plan nego- tiate on its own with drug companies. The administration insisted the managed care plans could do a better job of negotiating, even though the State was negotiating for a much larger population than any one managed care plan. In 2020, the administration reversed course, enacting a plan to return the drug benefit to the PDP by May of 2021. In the interim, the administration was to find a solution to the problem faced by providers in the federal 340B program who would lose operating revenue from being carved out from managed care. By March of 2021, the 340B issue was still not resolved and the administration agreed to a delay of the carve-out plan for two years.
This bill would restore the PDP's power to negotiate drug prices for the entire Medicaid population, representing over six million "covered lives ," by having the PDP administer the drug benefit, while at the same time keeping the 340B program intact within managed care. Managed care plan enrollees would use their plan membership card for drug benefits. Medi- caid would bill each Medicaid managed care plan for the drugs provided to its enrollees and return the amount through the premium rate that the State pays the plans. This would be consistent with integrated care, care coordination, and "value-based" payment models. It would more effectively hold the managed care plan or provider network accountable for the total cost of care, while still giving the health plan (and the State) the benefit of lower drug prices.
Legislative history
2015-2016: A.9271 - reported to Ways and Means committee
2017-2018: A.4233 - reported to Ways and Means committee
2022: S9043/A7200A Gottfried
Fiscal implications
Undetermined savings
Effective date
This act shall take effect immediately, except for sections 1-5 which shall be effective one hundred and eighty days after becoming law.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.